Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# Heidelberg Epignostix GmbH

## Sitemaps

- [XML Sitemap](https://epignostix.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Heidelberg Epignostix appoints co-founder Prof. Dr. Dr. med. Felix Sahm as Chief Medical Advisor](https://epignostix.com/heidelberg-epignostix-appoints-co-founder-prof-dr-dr-med-felix-sahm-as-chief-medical-advisor/) - Heidelberg, Germany, June 1, 2026 – Heidelberg Epignostix GmbH, a deeptech company committed to transforming cancer diagnostics through DNA methylation-based AI classification, today announces the appointment of Prof. Dr. Dr. med. Felix Sahm, MD, PhD, MBA as Chief Medical Advisor. In this new role, Felix will advise the company's clinical and medical strategy as Heidelberg Epignostix
- [Epignostix launches advanced DNA methylation-based sarcoma classifier](https://epignostix.com/epignostix-launches-advanced-dna-methylation-based-sarcoma-classifier/) - Heidelberg, Germany, July 8, 2025 – Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces the successful launch of a substantial update to their sarcoma tumour classifier- marking a substantial milestone in establishing precision tumour classification beyond tumours of the central nervous system. Combining epigenetics with artificial intelligence-powered bioinformatics, their software algorithms enable precise cancer classification of
- [Epignostix announces CMS release of a preliminary gapfill price for their proprietary CPT Code for the Epignostix CNS Tumor Methylation Classifier test](https://epignostix.com/epignostix-announces-cms-release-of-a-preliminary-gapfill-price-for-their-proprietary-cpt-code-for-the-epignostix-cns-tumor-methylation-classifier-test/) - Heidelberg, Germany, May 6, 2025 Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics, announces today that the Centers for Medicare & Medicaid Services (CMS) have released a preliminary Medicare reimbursement rate for the CPT® (Current Procedural Technology) code for the Company’s proprietary Epignostix CNS Tumor Methylation Classifier - a molecular test for precision diagnostics of tumors of the central nervous
- [Heidelberg Epignostix is live!](https://epignostix.com/epignostix-is-live/) - Heidelberg, November 2023 - We are thrilled to announce the arrival of Heidelberg Epignostix GmbH, a pioneering force in molecular neuropathology, with a mission to revolutionize cancer diagnostics by applying AI-based approaches for epigenetic tumor classification. Based on an exclusive license to IP from the world-renowned German Cancer Research Center (DKFZ) and University of Heidelberg,
- [DKFZ spin-off Epignostix raises €4.3m seed round to commercialize diagnostic tumor classifier](https://epignostix.com/dkfz-spin-off-epignostix-raises-e4-3m-seed-round-to-commercialize-diagnostic-tumor-classifier/) - Heidelberg, Germany, July 2, 2024 – Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces €4.3M in seed funding. This investment will enable Heidelberg Epignostix to make a substantial leap forward in driving market development for its flagship indication for brain tumor classification. CARMA FUND I Capital GmbH & Co KG led the
- [Heidelberg Epignostix appoints Helge Lubenow as CEO ](https://epignostix.com/heidelberg-epignostix-appoints-helge-lubenow-as-ceo/) - Heidelberg, Germany, July 16, 2024 – Heidelberg Epignostix, a deeptech start-up committed to precision cancer diagnostics today announces the appointment of Helge Lubenow as CEO. She will be succeeding founder David Jones in the role who will continue to support Heidelberg Epignostix as Chief Scientific Officer. Helge Lubenow has almost 25 years of industry experience and
- [Epignostix launches CNS and sarcoma diagnostic tumor classifier applications](https://epignostix.com/epignostix-launches-cns-and-sarcoma-diagnostic-tumor-classifier-applications/) - Heidelberg, Germany, January 22, 2025 Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces the successful launch of their CNS and sarcoma tumor classifiers- marking a substantial milestone in driving market development for their flagship indication, CNS tumor classification, and expansion to additional applications. Combining epigenetics with artificial intelligence-powered bioinformatics, their

## Pages

- [Terms of Use](https://epignostix.com/terms-of-use/) - In the following, we would like to present our Terms of Use, which we apply to the no-cost use of our Classifier. The Classifier is an AI-based tool (“Tool”) that can be useful to predict biological tumor classes from methylation profiles with high accuracy. The Tool is a research tool that provides research results which
- [Terms of Use (archived)](https://epignostix.com/terms-of-use-expiring/) - In the following, we would like to present our Terms of Use, which we apply to the free use of our Classifier. The Classifier is an AI-based tool (“Tool”) that can be useful to predict the tumor class from methylation profiles with high accuracy. The Tool is a research tool that provides research results which
- [Product fact sheets](https://epignostix.com/product-fact-sheets/) - CNS Tumor Methylation Classifier Epignostix-CNS-Classifier-Product-Fact-SheetsDownload Sarcoma Methylation Classifier Epignostix-Sarcoma-Classifier-Product-Fact-SheetDownload
- [Account](https://epignostix.com/account/)
- [About Us](https://epignostix.com/about-us/) - We are Heidelberg Epignostix, a pioneering start-up composed of a dedicated team of experts in the field of DNA methylation-based tumor classification. Based in Heidelberg, Germany, our company is built upon the rich knowledge and extensive research experience of our team. At Heidelberg Epignostix, our mission is to revolutionize tumor classification by harnessing the power
- [Our technology](https://epignostix.com/our-technology/) - Our technology Our Technology We improve cancer classification by combining epigenetics with artificial intelligence The cancer epigenome is a combination of two things: changes in the DNA that happen as the tumor grows, and specific characteristics that show where the cancer started from. This interesting feature allows us to track and find the original source of a
- [Sarcoma methylation classifier](https://epignostix.com/our-technology/sarcoma-methylation-classifier/) - Previously available under the MolecularNeuropathology.org website, our sarcoma methylation classifier is now available on our portal. It currently supports both Illumina Human Methylation EPIC v1 and EPIC v2 BeadChip arrays, as well as the older 450k platform. METHOD Our sarcoma classifier is trained on a well-annotated reference set of 1,077 samples covering 62 classes of
- [Video Tutorial](https://epignostix.com/our-technology/our-technology-cns-tumor-classifier/video-tutorial/) - This is a step-by-step video tutorial of the Heidelberg Epignostix Classifier App! In this video, we’ll guide you through the process of registering on our website, uploading your data and downloading your Classifier report.
- [FAQs](https://epignostix.com/our-technology/our-technology-cns-tumor-classifier/faqs/) - Welcome to our Frequently Asked Questions (FAQs) section. Here, we have compiled answers to the most commonly asked questions about the Research Use Only (RUO) Tumor Methylation Classifiers that we offer via the Epignostix website. In addition, we provide a video tutorial where we guide you through the process of registering on our website, uploading your
- [CNS tumor methylation classifier](https://epignostix.com/our-technology/our-technology-cns-tumor-classifier/) - Previously available under the MolecularNeuropathology.org website, our flagship CNS tumor methylation classifier is now live on our portal. It currently supports both Illumina Human Methylation EPIC v1 and EPIC v2 BeadChip arrays, as well as the older 450k platform. METHOD Our classifier is trained on a well-annotated reference set constituting 7,495 samples covering 184 subclasses
- [Team](https://epignostix.com/about-us/team/) - The Heidelberg Epignostix team brings together leading experts in the fields of genetics, pathology, medicine, data science, molecular biology, bioinformatics, artificial intelligence and business. Helge Lubenow Chief executive officer David Jones Chief scientific officer AND CO-FOUNDER Daniel Schrimpf Head of software development and CO-FOUNDEr Martin Sill Head of Data Science and co-founder Areeba Patel Head
- [Legal notice](https://epignostix.com/legal-notice/) - Heidelberg Epignostix GmbH c/o BioLabs Heidelberg Nikola-Tesla-Straße 1 69124 Heidelberg Contact: Contact us CEO: Helge Lubenow Contact via Email Form District Court Mannheim, HRB 745601
- [Change Password](https://epignostix.com/change/)
- [Profile](https://epignostix.com/profile/)
- [Login](https://epignostix.com/login/)
- [Forgot Password?](https://epignostix.com/forgot/)
- [Reset Password](https://epignostix.com/reset/)
- [Register](https://epignostix.com/register/)
- [Privacy policy](https://epignostix.com/privacy/) - The Heidelberg Epignostix GmbH (“Epignostix”) developed an AI-based Molecular Neuropathology Classifier (“Tool”) which can be used by medical professionals to predict in particular the central nervous system (“CNS”) tumor class or sarcoma tumor class of new unseen methylation profiles. The Tool can be used as a local copy and installed by the medical professionals (“User”)
- [Disclaimer](https://epignostix.com/disclaimer/) - Publisher: Heidelberg Epignostix GmbH Represented by: Helge Lubenow c/o BioLabs Heidelberg Nikola-Tesla-Straße 1 69124 Heidelberg Email: info@epignostix.com District Court Mannheim, HRB 745601 Disclaimer: Our goal is to keep this information up to date and accurate. If errors are brought to our attention, we will try to correct them. However, we accept no responsibility or liability
- [Contact us](https://epignostix.com/contact-us/) - Heidelberg Epignostix GmbHc/o BioLabs Heidelberg Nikola-Tesla-Straße 169124 Heidelberg
- [Users List Item](https://epignostix.com/user-list-item/)
- [News](https://epignostix.com/news/) - Categories:
- [Register your interest](https://epignostix.com/register-your-interest/) - First name Last name Email Classifier Message Submit Your form submitted successfully! Sorry! your form was not submitted properly, Please check the errors above.
- [Cookie Policy (EU)](https://epignostix.com/cookie-policy-eu/)

## Gutena Forms

- [Contact Form](https://epignostix.com/gutena_forms/contact-form/) - First name Last name Email Classifier Message Submit Your form submitted successfully! Sorry! your form was not submitted properly, Please check the errors above.

## Categories

- [News](https://epignostix.com/category/news/)
- [Press Releases](https://epignostix.com/category/news/press-releases/)